Back to top
more

Urovant Sciences Ltd. (UROV)

(Delayed Data from NSDQ)

$8.44 USD

8.44
32,714

-0.14 (-1.63%)

Updated Oct 19, 2020 04:00 PM ET

After-Market: $8.36 -0.08 (-0.95%) 7:57 PM ET

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.33%
2Buy17.77%
3Hold9.37%
4Sell4.88%
5Strong Sell1.79%
S&P50010.56%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth B Momentum F VGM

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (177 out of 254)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Trades from $1

Company Summary

Urovant Sciences Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing therapies for urologic conditions. The company's product candidate pipeline consists of vibegron, an oral, once-daily, small molecule beta-3 agonist being evaluated in an international pivotal Phase 3 clinical trial for the treatment of overactive bladder. hMaxi-K, is a novel gene therapy being developed for patients with overactive bladder who have failed oral pharmacological therapy. Urovant Sciences Ltd. is based in Floor London, United Kingdom.

General Information

Urovant Sciences Ltd

11-12 STREET JAMES SQUARE SUITE 1 3RD FLOOR

LONDON, X0 SW1Y 4LB

Phone: 44-0-20-7400-3347

Fax: NA

Web: http://www.urovant.com

Email: ryan.kubota@urovant.com

Industry Medical - Biomedical and Genetics
Sector Medical
Fiscal Year End March
Last Reported Quarter 9/30/2020
Next EPS Date 11/3/2020

EPS Information

Current Quarter EPS Consensus Estimate -1.50
Current Year EPS Consensus Estimate -6.73
Estimated Long-Term EPS Growth Rate NA
Next EPS Report Date 11/3/2020

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 8.58
52 Week High 15.98
52 Week Low 6.55
Beta 1.25
20 Day Moving Average 73,163.30
Target Price Consensus 23.33

UROV

% Price Change
4 Week -11.73
12 Week -11.27
YTD -44.68
% Price Change Relative to S&P 500
4 Week -14.94
12 Week -17.59
YTD -50.55
Share Information
Shares Outstanding (millions) 31.18
Market Capitalization (millions) 267.54
Short Ratio NA
Last Split Date NA
Dividend Information
Dividend Yield 0.00%
Annual Dividend $0.00
Payout Ratio NA
Change in Payout Ratio NA
Last Dividend Payout / Amount NA / $0.00

Fundamental Ratios

P/E
P/E (F1) NA
Trailing 12 Months NA
PEG Ratio NA
EPS Growth
vs. Previous Year -5.32%
vs. Previous Quarter 36.94%
   
Sales Growth
vs. Previous Year NA%
vs. Previous Quarter NA%
   
Price Ratios
Price/Book NA
Price/Cash Flow NA
Price / Sales NA
ROE
9/30/20 NA
6/30/20 NA
3/31/20 -6,363.46
ROA
9/30/20 NA
6/30/20 -156.89
3/31/20 -155.51
Current Ratio
9/30/20 NA
6/30/20 2.36
3/31/20 1.89
Quick Ratio
9/30/20 NA
6/30/20 2.36
3/31/20 1.89
Operating Margin
9/30/20 NA
6/30/20 NA
3/31/20 NA
Net Margin
9/30/20 NA
6/30/20 NA
3/31/20 NA
Pre-Tax Margin
9/30/20 NA
6/30/20 NA
3/31/20 NA
Book Value
9/30/20 NA
6/30/20 -2.72
3/31/20 -1.90
Inventory Turnover
9/30/20 NA
6/30/20 NA
3/31/20 NA
Debt-to-Equity
9/30/20 NA
6/30/20 NA
3/31/20 NA
Debt to Capital
9/30/20 NA
6/30/20 NA
3/31/20 NA